Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.Frontiers in pharmacology · 2021
   Article
2. The Discordance of Gene Mutations between Circulating Tumor Cells and Primary/Metastatic Tumor.Molecular therapy oncolytics · 2019
   Article
3. Future paradigms for precision oncology.Oncotarget · 2016
   Review
4. Pragmatic medicine in solid cancer: a translational alternative to precision medicine.OncoTargets and therapy · 2016
   Article

Corrections and comments

• Comment on
  Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor.2012
• Comment on
  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as